Pharma & Health Business #37, Μαΐος-Ιούνιος 2016

GR1603458162

final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1 18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..

#035 -2 0 1 6

www . v i r u s . c o m . g rI S S N : 2 2 4 1 - 0 9 6 1

pi

pi

4 Clinical Research ConferenceThink Tank

001 EX.indd 1 3/3/2016 7:50:57 pi

/ #0

35

/

-

2

01

6ISSN

: 224

1-09

61

00 ANAPTYGMA EXOFYLOU.indd 1 3/3/2016 7:51:39 pi

/ #03

7 /

-

2016


#035 -2 0 1 6


pi

pi


001 EX.indd 1 3/3/2016 7:50:57 pi

/ #0

35

/

-

2

01

6ISSN

: 224

1-09

61


#037- 2 0 1 6

Jean-Michel Malbrancq

C

PFI

-02-

FEB

16

Pfizer, - , 1849 .

, .

C

M

Y

CM

MY

CY

CMY

K

AbbVie_bestworkplaces2016TEL2_21x28.pdf 1 4/7/16 2:00 PM

1GR-MEN-ADV-03/2016

Menarini_KTX_21x28_GREEK_03_16.pdf 1 3/3/2016 2:32:51

2 / - 2016

6.

8. Jean-Michel Malbrancq

16.

24.

29. : C

30.

34. I.H. Mameletzis

40. Infographic

42.

#037- 2016 10

: [email protected]

: [email protected]

: [email protected]

: [email protected]

- : [email protected]

[email protected]

[email protected] - : [email protected]

: [email protected]

08

24

34

3 & : -A [email protected]

DIGITAL MARKETING: [email protected]

: [email protected]

& : [email protected]

: [email protected]

: [email protected]

: Shutterstock

- : Pressious ....

:

29, 174 56

48.

C

52.

C

56.

60.

68.

71. Virus

76. VRS

78. 30

,,,

T: 210 9984950, : 210 9984953 E: [email protected] www.virus.com.gr www.phb.com.gr

www.ethosmedia.eu www.ethosevents.eu www.alivemag.gr www.hrima.gr www.insuranceworld.gr www.asfalizomai.com

ISSN: 2241-0961

56

16

42

E D I T R I A L

4 / - 2016

,

,

...

editorial

...

. -

7,5 . .

. ;

: 7,5 ., 5,3

. -

2,2 . ,

-

5 . !

,

(, -

)

3 . !

700 .

5 ,

.

5 ...

. , ,

...

200 -

.

. ,

600 .

!

-

. -

, ,

-

.

,

.

, . -

, ,

, -

.

.I .

.

Gilead Sciences , . .

Gilead ( HIV/AIDS ), ( ) / .

, 42% . .

998/

GR

/12-

01//1

003(

2)

5 .I .

.

Gilead Sciences , . .

Gilead ( HIV/AIDS ), ( ) / .

, 42% . .

998/

GR

/12-

01//1

003(

2)

6 / - 2016

- . - , site -, - . , , , , . - , . , , - , , .

*

, - . - - , - -, - . - - . , , . . , , . , () . - , . - .

7*

- , - - . , , - , - , - - . - - (). , , , - . PhB , - , . , - , - . , PhB, -

2007 - - . - 10 , . - . - , , . - PhB . , -, , -. - , . , , .

, - . - , PhB - - , . - - - , . , -, PhB. , , , , . , - , -

8

/ - 20168

/ - 2016

9 - - - Jean-Michel Malbrancq, GE Healthcare . . : - ... - . ,

. - - -, . GE, , - -: . -, , - (, PET), - ...

H PhB GE Healthcare .

:

* GE Healthcare

Jean-Michel Malbrancq*

9

A MD, MSc, PhD, & , Jean-Michel Malbrancq, & CEO GE Healthcare Europe

10

/ - 2016

_ , , - , . . ; ;

_ - . 15 , GE 7 . - PET-CT - , - - . -, , , -, .

_ PET-CT Discovery IQ. ;

_ 70%, -

70% - . - , . Discovery IQ PET-CT - . PET CT, - -. - . - - - .

_ Jean-Michel, GE 30 ! PET-CT. ;

_ 30 , -! GE , - - PET-CY, -, . PET-CT - .

, ,

,

11

PET-CT 2001. - : , , - - - . - PET-CT - , - - , - . GE - - PET-CT PET-MR.

_ , - PET-MR. ;

_ PET-CT, PET-MR - , -. , . , PET-CT - 95% . PET-MR, - - - . - -, , - .

_ - healthymagination. -; GE;

_ Healthymagination : - - , , , ,

- . - , - . - . Vscan GE : , - - - . , , - - - (, ..). , - , .

_ - - . . , - . GE;

_ , - . - - , - . . , - . - - : - , . ,

12

/ - 2016

- . GE - -. , 1 . . . , - . , - - . - - , .

_ , - ;

_ , PET-CT PET-MR, - , . , , - , - (, PET), . GE Health Cloud, , -, , , . -

.

_ GE - -, - , . , - -, ;

_ - : -, - . . , - , . , - , - . , , . GE - , - - .

Jean-Michel Malbrancq 13 1956. - Compigne 1980. 1983 1987 Thomson CGR, -, GE 1987, . 1987 2005, GE ,

Jean-Michel - , - , - - (CT) 2001. 2005, Milwaukee . , - ,

. 2009, Jean-Michel GE Healthcare , 2011 - - . , 20 , . - .

Who is who

Healthymagination

13

GE Medical Systems GE Healthcare Technologies, - GE Medical Systems , , , -. , - - . - :

- (MRI)

- (CT)

--(Vascular-Cardiovascular)

(Nuclear Medicine)

-- (PET-CT)

- - (X-RAY)

(Mammography)

(Ultrasound)

(Bone Mineral Densitometers)

- (Monitoring)

- (PACS, ..)

, GE Medical Systems GE Healthcare Technologies - - , , - , :

-

.

.

, - .

- - internet - iLink, InSite.

- .

- .

, , , nSiteTM GE Medical Systems GE Healthcare Technologies (), USA (Milwaukee) (Tokyo), - - 45 . 2004, GE Medical Systems - Amersham Health, , , GE Healthcare, - - , - - , , - - .

H GE Healthcare

PET-CT

14

/ - 2016

, 15 -. , - GE Healthcare. - , PET/CT , - 5 . , GE Healthcare - PET/CT Discovery IQ , - - MR Optima 450W with GEM Suite GE Healthcare, 1.5 Tesla. , - -

, . , -. -, PET/CT

.

, 61% clawback rebate, , -, 18 . - 2007-2011. - , , - , , , . - -, , . , 10 5 ! , - (PET/CT) - (CT) - - (), - . - - . - -, 18 . , - - MR Optima 450W with MR Optima 450WGEM Suite GE Healthcare, 1.5 Tesla. - , , -

, PET-CT

PET-MR,

15

, . GE Healthcare , Jean Michel Malbrancq. - , -, , , , - - 70% 2 - Malbrancq. , - - . , -. , - PET/CT, - . GE Healthcare 2005, 2009 - GE. - - - .

, - 5 1.000 2.200 .. , - -. - . , , ( . ), . , 180 60-90% .

15

16

/ - 2016

! , , - (). , - - - . -, , . PhB

, , . - PhB . - , , - . , 35 , - , - - . -

PhB , , .

.

18

/ - 2016

. , - - . , , . - , , . 350-400 . . - , - , - . , - , . , -, . - :

- - . - ,

- - . , - , - . . - - , - . , - -. - :

(-, , -).

- - , - , , , - .

- , - , - .

- (), - (, -, ..), - . , ,

PhB

.

19

- - . - , - . - - , , . - - , . (-) , - ( ), .

- - - . - . - , . - . - , : - . - - , -, , . - , . - - . -

, - , - . (peer to peer) - . 8 .. 8 .. , - -, , , - . , - , , - 24 - , . - , -, :

- -

(, , - , , )

-

-

(,

)

-

. -

( , ).

-, , , .

350-400 .

20

/ - 2016

, -, - , .

- (- , , -, ).

- - .

, - , - - - .

- .

- - .

- -.

, - , , .

- - -, .

- - , , , ,

- .

- , - - .

- .

, , - . , - -. - . . -, :

-

-

/-

, , , -

21

.

- - , ( , -, ..).

, -. - , , - - . - , - , - .

- - gatekeepers, - , - , - .

, - - , , , - , - , - .

-

, - . - . - , - , - - .

() - (-, , ), - (, , , ).

, - , - - , - .

- , - - .

, , - , , - - .

12 10.000

22

/ - 2016

:

-- - . , - - - , , - . , -. - . - , . - -

, - . , - - .

, 2.000-2.500 - , 1.000 , , 12 (4 , 1 - , 2 - 2 , 1 , 2 - ) 10.000 . - 1/4 - 20.000 . -, , - . -

,

2016 2017 2018 2019 2020

500.000 1.250.000 2.250.000 3.250.000 4.250.000

% 8,285 . / 6% 15,2% 27,2% 39,2% 51,3%

% , 4,5% 11,3% 20,4% 29,4% 38,5%

27.314.899 1.229.000 3.091.000 5.572.000 8.031.000 10.401.000

, ,

420.000-

480.000

23

- . :

. (- ).

. - , - .

- 4 . - (, - , , - ..).

(2016-2017) / 40-50 - ( 5% )

(2018-2020) -- .: 5 ( 25% )

(2021-2027): - (80% )

,

, - 420.000-480.000 . , , 350-400 . , - 0,2-0,3% 3-4% - . - ( , - ..), - . - , -, , - 60-70% , - . - - . , 27,3 . - 2014 : 11,9 . 9.189 -, 6,1 . 2.306 - 9,3 . 5.384 -. , - , -, . () - (1.299 ) (2.644 ).

2016 2017 2018 2019 2020

/ ( : 1.724 .//) 712 1.793 3.232 4.658 6.033

% 5.384 , 13,2% 33,3% 60,0% 86,5% 100%

( / : 120 . 5.384 ) 15,86 . 39,96 . 72,0 . 103,8 . 120 .

16,0 55,8 . 127,8 . 231,6 . 351,2 .

/ 0 0 21,25 . 74,38 . 170 .

24

/ - 2016

26 2016, (...) - - . - - . , - ( -), - - 2010. ... - (), -

, - - HIV . - , - , - -. - , , . , , - , - , - -

:

...

2020

25

2020, - - . - 2013. - , 1.

, -, ..., . . 1, 1980-2011 -, ... -15 ( ). , . 2 - -15. . - , , -. , - , 1970, , - . , - - - , .

-, , - - 15 (. 3).

1 AIDS/HIV 2011-2013.

26

/ - 2016

- , , - , - , , . - , . , ,

- . , ... 2014 66% 55% -, - , -. - , , - , - . - , - -15 (. 4). , , HIV/AIDS. , HIV - - (. 5).

- ... () 1983, - . - - , , - . - - , . - , - - 1953, 1983, , -: - , , -, -. , , . -

27

- , -- (. 6), - - (. 7). , - , ... (. 8). , -, ... , - . 2009 2012, - , - 22%, - , 24%. - , . , - 20%. , - -: 4,0% 2009 7,8% 2013. 26% 2013 ( 8% 2000), - -15. , - - -

. - , , - -. , , - ( , 2009-2014) . , , , -, - . , - , - 2000, - -. , - - 15 (+ 67% + 80%, ), - - -15 (-59% -27%, ). - - 2020 .

: hamburger

28

/ - 2016

2020 - , - , , , , -, . - - , -- ( 1). 19 - - , : , Gini . - (- , , -), - . , -, - ... 2004 (-15). - , 61%

50 - - , - . , -

- 2020 - .

... : http://goo.gl/pXs4zU

2020

30

34I. . Mameletzis:

42. :

48: C

C

30 / - 2016

- - - C. , - ... , , , 20 2016,

- - C (Gilead, Bristol-Myers Squib, Abbvie, Janssen MSD). MSD - , -. , -

, C.

HEP C

31

: C

, - , 13 . , - 2012! , - - -, - 2016. , ... -. , . - , -, (Health Technology Assessment), . -. . -, -:

- - . - - , - - .

- - - , 13

32 / - 2016

C (HCV). , C - . - . 15% . - , -, , , . 80% .

10-20 , 10-30% 30 - . 2013 - -- ( ) . , -, 50%, - HCV, 1. , . , 40%

1, - 3, 15% 4 5% 2. 2014, - , - Gilead. - daclatasvir Bristol Myers Squibb, - - Abbvie, Janssen MSD. 100%!

(Budget Impact Analysis). -, - .

, - . - . - , - - . , - , - . , . , -

... , , - - , . - - - . 30.000 , 15.000, -, -. , , - 22.000 . , , - 1.400 . , , 160-170.000 - C. -, (80%) , . , . , , , - . .. , . , - , .

-

-

HE15013_21X28_HR.pdf 1 15/09/2015 9:50 ..

34 / - 2016

-, , - PhB, , - (...), H. . ..., , 69 , - . C - , - . - , - - . -

, - , - , , -. , , - , , , - . , -, C , - - . - C - .

... PhB - , Ioannis Hodges Mameletzis, - - HCV - .

:

:

...

35

: C

* HIV, ...

I. Hodges Mameletzis*

36 / - 2016

_ - ... - C ;

A_ , C, ... 90% 65%, 2030. , - (HBV) C (HCV). HCV -, -, .

_ ; , , ;

A_ - - , , . - -, -. , , . - HBV, , - - , ( ) - HBV HVC.

_ , ;

A_ - - ( ). , HBV HCV, . B - C - . - C 2030, 90% .

-

, -

-

37

: C

C, - 80% . -, - . , , 2030 ( ). 300 . , . - - C -, . - . - . , , , - . - HIV HCV - . - -. . , , - . , , ... .

_ - ;

A_ 2016, - 25 36. - . , , , , -, . , - . - ( ,

C) - . -, - , , , - .

_ - , ;

A_ - - . , - , . - HIV - . , , , . . - - HCV.

_ - - ;

A_ - ... - . , - , . - - . - - . . - , - . , , ,

,

38 / - 2016

- . - -, . . ; - ( )

, - ( , , , sex workers, -, - ). , . -, , , - , , -, , , - , , . , - , . - , . -, . , -

. . - - . C, - , . , , . -

, . - . . , . C HIV, . . . - -. - - , - . , -

C 2030,

90%

39

: C

C . , , - ( , , HCV, - ).

_ , - ;

A_ -

, . - HCV, , - -. - . , - HCV. , - . , - , . - ..., - .

_

, ;

A_ , - . , - - (European Center for Disease Control-ECDC), ... . , , .

, , . - . - . ... - . - , , . , - HIV - , - . , ...

- 194 , 28 2016, 69 - ..., - . 2030. - ... - , 65% - 80%, 7,1 - . - , - - - World Hepatitis Alliance, Raquel Peck. - , World Hepatitis Alliance 230 - -, (28/7), NOhep, 2030.

40 / - 2016

C

1945-1965;

1945 1965

5x C

3 4 ATOMA C

-, - C (HCV), 1989, 170 - , - 133 . , - C . :

(50-70% C 5 - ).

- ( ).

.

( 2-5%, - 30% HIV ).

- C. (1%).

piercing - ().

, , - ...

1992. , - .

, C - , - 1945-1965 - 5 , FDA .

, , , 1992 HCV.

I N F O G R A P H I C S

C

41

: C

, , . .

C

75%

C

1945-1965 (CDC)

HEP Cblood test

C

C

C o1

C

42 / - 2016

C - , PhB - , . , - , - , . - , , , - . , - - , , - .

, - . - C, - , - . , - - , . 28 , 194 - ..., - 2030.

C, , PhB .

:

:

*

43

: C

*

44 / - 2016

_ C ;

_ , 1,3%-1,6% , - 133.000 , - C. - C , - - . , C, , . - C , - . - -. , - , . , - - , , . -

, , , .

_ , , ;

_ C - . - 170 - C. , - , 133.000 - , - 20% -. , - - . , 3.700 - C, , , -, - . - . , C . - , , , -

C

45

: C

. , , - C - - . , - . , - - .

_ -, , ;

_ -, - - C . 1992, C, - (). -, - , - , - . -, C - 80%.

_ - C;

_ , - - C. , - - - -, - -.

- 2014, - , - - . 24 , - 100%, - C. - , .

_ C, , , - , -

46 / - 2016

. ;

_ - , - , - . - - - C ,

. , , C, , - , - . , - , , - - , - 50%. , -

C - . -, - . , - - .

_ - ;

_ - C - . , - - , - - .

_ - - , ;

47

: C

_ , - . - - , , C. - . - -, , , , , -.

_ - ; ;

_ - - . 28 2016, 194 - ... -, - 2030. 69 , -, - , - -, , - B C.

- B C 2030 - - -, 65% 80%, 7,1 - . - (...) 2030 -

. , - C - , - ( , , ), - , - , - - . , , - - .

48 / - 2016

C - . - , 130.000 C. - C -, -

, . C - , - - 1992, 40%

HCV .

,

-

,

C

49

: C

C (HCV) - - . HCV - . - HCV RNA 12 24 -, - (sustained virological response, SVR). HCV 1989 2011-2012, -- (IFN) 15- - (PEG-IFN), , (RBV), . PEG-IFN RBV 24-48 SVR 40-80% , - HCV. , PEG-IFN RBV -, , - . (2011-2014) , C - . - (boceprevir telaprevir: HCV) PEG-IFN RBV 1 - SVR 1, - , PEG-IFN RBV. , (2014-2015) - . 2014, () C. , -

50 / - 2016

HCV (sofosbuvir), (simeprevir), NS5A (daclatasvir), - sofosbuvir NS5A (ledipasvir) - , - (paritaprevir/ritonavir) - NS5A (ombitasvir) - (dasabuvir). , : (grazoprevir) NS5A - (elbasvir) sofosbuvir , NS5A (velpatasvir) .

. . , C , , - - sofosbuvir, - (- 95% , - 3 (- ) - SVR

51

: C

www.bms-greece.gr

52 / - 2016

2016, - (CHMP) - (EMA) - / - C. , - . -- -, - - (SOF) 400 mg - NS5A, (VEL) 100 mg. -/ Gilead Sciences 3:

ASTRAL-1, ASTRAL-2 ASTRAL-3, 1.035 - HCV 1-6, -

( Child-Pugh), 12 .

ASTRAL-4 267 HCV - 1-6 ( Child-Pugh), - 12 , -/ 24 .

- - 12 - (SVR12). CHMP - / . -, , 2014. , - /, , - 2014.

C

Sofosbuvir/Velpatasvir 52

Ombitasvir/Paritaprevir/Ritonavir + Dasabivir 54

Elbasvir/Grazoprevir 53

55

:

Sofosbuvir/Velpatasvir

53

: C

2016, - (CHMP) - (EMA) - /, - - - , 2.000 HCV, 20 , . , MSD ( Merck & Co) - SVR12 SVR24, , 12 24 - . -/ - 3:

C-EDGE Head-to-Head, - / Sofosbuvir Peginterferon/Ribavirin (pegIFN/RBV), HCV - 1 4 ,

- pegIFN/RBV.

C-EDGE IBLD, / HCV - 1, 4 6, - .

C-EDGE CO-STAR, - /- HCV 1, 4 6 .

, -/ - 28 - - , , C. H 2016, - 2016 , , 2017. /- - (FDA) 2016 - .

Elbasvir/Grazoprevir

54 / - 2016

2016, - (CHMP) - (EMA), - -//- - C 1b (GT1b) - ( Child-Pugh). CHMP -

3b TURQUOISE-III, - AbbVie C, 1. - - , 100% C 1b - ( Child-Pugh), - , 12 .

Ombitasvir/Paritaprevir/Ritonavir + Dasabivir

55

: C

, - () - -, - C, - - C1. - - - . - - - - C . , , -, . -

14 2016, - - C - , C - -. - - (PRAC), - (CHMP), . - - , - - . - , - - - - .

1 -: Daklinza (daclatasvir), Exviera (dasabuvir), Harvoni (sofosbuvir/ledipasvir), Olysio (simeprevir), Sovaldi (sofosbuvir) Viekirax (ombitasvir/paritaprevir/ritonavir).

56

/ - 2016

- , -, . - 49 , - E.coli, , - , -. - , , . -

, , . - -CDC ( ) - - , Reuters, Washington Post New York Times. , , 2015, - , , . - , . , . - - -

100 . .

CDC

49 E.coli,

58

/ - 2016

, , - CDC, , - . 49, 26 -, Antimicrobial Agents and Chemotherapy - . -E coli , mcr-1, - . - , - , - , - , - , . , - - 10 - , 100 . . - 2050, - - . - 40 . .

, , -, . 4,7 . . -. , , , -, . , - 1 . . - - , .

, - - David Cameron, - . , - - , - , - . , 2020 - . , . , - , - , -. : - , - ( 80), - - , - . , - ( 70% ) -

10 .

59

. , - - 2 . . ( -), , - - .. - -, - , .

, - , - . , , , - - . 14 . 12 17 -, . - . - -. . . - - , - . - , - . , -2 . - .

, , -, -, - . - - , - .

, - , . , , -, . James Tiedje, Michigan State University, - - - - . - - . - - . - , -, - , Tiedje. - - , - . , , - , .

, 100 . .

40 . . 10

60

/ -I 2016

- (..). , . ( 3()/. 18910, 390/21-3-2013), -, , - . -, .. . .

, . - , (), , , - . - .. - () . -

:

,

([email protected]),

, . ,

Supply Chain and Logistics Manager([email protected]).

61

- - , , ... .., , .., - -. - .., - , -, , .. - - . , ( , - ..). .., - 536/2014 , - , . - .., - - . 80.000.000 , 300.000.000 - 1 . (!), -. , - .. . - , - ( ) .

62

/ -I 2016

,

,

- - (/) ( 3()/. 18910, 390/21-3-2013), - 146/03 (- ) (3) (, ) . , , - , . , , - - , / - , , , - , , - - . - - - .

/ - ,

- , . - . -, , , , . - , - (500) , - ( 1). -, , 15% - , - - , - /. - 5% , . - , - ( 2). , - , - - ( 3).

63

, - , ( 4).

- (4) - - (3) , 146/2003. - .. . , 1 - 3919 -

, 75.05.09 , 96.75.09 . 2 - 15-20% - 3913 -, 75.05.05 . , 96.75.05 - , . - - , - .. .

, -, :

96.75.05., ,

96.75.05.., - .

- 1 2 - , - - -. , 3 4 -

, . , - - , 73 , - -. -. - - 92.00. , . , - 96.73 , .

64

/ -I 2016

1/4/2015, - ( 7 . 3329/2005 81//2005). - , - ( 8 . 4308/2014, 1003/2014 . 8.1.1 & 8.9.1). , - .. (500 15%), - , - . , 500,00 , - () - ( 1). , .. 15-20% ( 2), . - - , - () , ( 4). , - , -, 5 241 .

.. - , . , -

- . - , -, (, - ) .

.. . :

, , . - .

( ) -, - . , . , , - .

- .

- . , - , , - , , ,

,

65

( - , ).

, - - . - - , , - , -

. , , , .. - - .

, - .. .

1.

30.00. 500 06.10.3919 500 90.07.75 500 75.05.09 500 06.21.3919 500 96.75.09 500 1.

38.03. 500 06.21.3919 500 _ _ _ 30.00. 500 06.31.3919 500 2. 15-20% / ( 5.000 )

30.00. 5.000 06.10.3913 5.000 90.07.75 5.000 75.05.05 5.000 06.21.3913 5.000 96.75. 5.000 2.

38.03. 5.000 06.21.3913 5.000 _ _ _ 30.00. 5.000 06.31.3913 5.000

3.

( . 2.500 )

_ _ _ _ _ _ 92.00. 2.500 92.00.09. 2.500 .99

4. ( 3.000 )

30.00. 3.000 06.10.3149 3.000 90.07.73 3.000 73.05. 3.000 06.21.3149 3.000 96.73. 3.000 4.

38.03. 3.000 06.21.3149 3.000 _ _ _ 30.00. 3.000 06.31.3149 3.000

A

86 / 2011

courier

cargo

logistics

!

C.C.L. :

100, 151 25 ,: 210 8056550, FAX: 210 8056553www.tachydema.gr

:E.E.T.T. A.M.: 03-017

, ...

1

(, , , ...)

86-87.indd 86 22/12/2011 5:28:03

87

courier

cargo

logistics

!

C.C.L. :

100, 151 25 ,: 210 8056550, FAX: 210 8056553www.tachydema.gr

:E.E.T.T. A.M.: 03-017

, ...

1

(, , , ...)

86-87.indd 87 22/12/2011 5:28:03

68

/ - 2016

- , - , , , - - Reputation Institute, - , 14 . , - 23.000 15 , - -. 7 :

1) , 2) , 3) , 4) , 5) , 6) 7) .

, - , - - Bayer, 4 7 -. - Abbott Laboratories, Novo Nordisk ,

Bayer

Reputation Institute

70

/ - 2016

Roche Merck & Co . , , - , 2015. , , - . Bayer Novo Nordisk 7 , - - , Reputation Institute.

- -, , , , , - . -, , , - - Kasper Ulf Nielsen, executive partner Reputation Institute, -: ,

- - . 18-24 , - .

Bayer, Abbott

Novo Nordisk

Reputation Institute

1. Bayer/ 70,6

2. Abbott Laboratories 68,7

3. Novo Nordisk 68.5

4. Roche 68.4

5. Merck & Co 68,3

6. Sanofi 67.8

7. Allergan 67,5

8. AstraZeneca 67,1

9. Eli Lilly 67,1

10. Abbvie 67.0

11. GlaxoSmithKline 66,9

12. Novartis 66,7

13. Bristol-Myers Squibb 66,0

14. Pfizer 65,9.

... , .

PhB . , , .

, , . .

, . ... .

, .

V I R U S

72 / -Io 2016

!

4 .

-. PhB -, . , , -

, . - - - ..., - . : - .

, - - . , , , - , .

M , , , , 4 . . - . 2% , - . , - . , .

73

social media!

M - - Facebook Twitter , . , , PhB -- - ,

-. , -, Facebook, - like - . , social media. ,

, . , - . PhB - . PhB - - . , , . - .

In Brief -! - - . - - - , , -. , , - , -. , , - 30%, 80%.

V I R U S

74 / -Io 2016

. -

. PhB. - 40 , . . . 4 . , - . - . , . , , . . , , - PhB.

In Brief

! - - , - , -. , - , - - , . - . , , .

A - . , - , PhB

- , . , , . , - -

, . , - - - , .

76

A

/ -Io 2016

Baxter International -

, - - . 1931 -. - 30 - 120 .

2016 ( ), - 2,37 . . - 3,38 . . (- ).

[BloomBerg TIcker: BAX:US ] [reUTerS TIcker: BAX:N]

BAXTER INTERNATIONAL INC. ,

:

, , . , VRS VRS . , , .

VALUATION & RESEARCH SPECIALISTS (VRS) - www.vrs.gr 104, 10564 . 210 3219557, 698 3603160 Email: [email protected]

& . : 2 0 0 2

52 ( )

P/E

(x)

30

25

20

15

10

5

0 2015 P/E P/E 2016 S&P P/E 2016 STOXX 600 P/E 2016

: FACTSET, VRS.24,8

15,917,6

15,9

50

45

40

35

30

252/6/2015 11/8/2015 20/10/2015 29/12/2015 8/3/2016 17/5/2016

:

3 2016

( . )

$43,48

. ( .) 552,26

. ( . $) 24.012,40

. . (52 .)

8.401.096

Beta 0,80

. 52 . ($) 46,25 USD

. 52 . ($) 31,98 USD

. 1- -1,75%

. 6- 17,57%

. 12- 24,60%

: ,

77

, , . , VRS VRS . , , .

VRS SFiT 104, 10564 . 210 3316358, 6945 851420 Email: [email protected]

V R S - S F i T: . : 2 0 0 2

& 2009-2015 (, . . ) EBITDA P/ P/BV EV / / ROE (x) (x) EBITDA % (x) (x)

2010 12.843 2.647 1.890 1.427 16,8 3,7 10,5 0,67 22%2011 13.893 3.575 2.809 2.256 10,6 3,5 7,8 0,73 33%2012 14.190 3.799 2.889 2.326 10,3 3,4 6,7 0,69 33%2013 9.413 3.313 2.550 2.012 11,9 2,8 8,3 0,72 24%2014 10.719 3.989 3.052 2.497 9,6 3,0 7,4 1,02 31%2015 9.968 2.135 1.180 968 24,8 2,7 12,9 0,65 11%

: / . : (3 2016), 2016.

2010-2015 (, . . ) . . 2010 2011 2012 2013 2014 2015

12.843 13.893 14.190 9.413 10.719 9.968 ( .) 6.885 6.847 6.889 5.251 6.138 5.822 % 46,39% 50,72% 51,45% 44,22% 42,74% 41,59% 1.427 2.256 2.326 2.012 2.497 968 % 11,1% 16,2% 16,4% 21,4% 23,3% 9,7% 2.685 2.905 3.270 2.733 2.925 2.213 126 140 149 243 94 101 2.371 2.628 2.803 3.499 1.577 1.604 64 64 62 113 64 63 2.265 2.420 2.425 2.911 1.884 1.731 234 235 260 338 159 167 4.411 4.409 4.899 4.866 2.677 2.666 Operating Cycle 190 204 211 356 158 164Cash Cycle ( ) -44 -31 -49 18 -1 -3

: / . : (3 2016), 2016.

.

.

S&P 500 5

( = 100): ,

180

160

140

120

100

80

60

4022/6/2011 22/6/2012 22/6/2013 22/6/2014 22/6/2015

S&P 500 METOXH

78 / -I 2016

!

;

-: -, -, . , - -. , , . -, - , . -

, , , - . -, , , - . , - . , , placebo ( ) ( - ). - .

- - . , . , -, , . , -

, , - , , . , - , -, , - , - . , - 20.000 - 13 , 70% - .

, ! - - . 5.000 , , - - , -

! , 30 -, - . , , 20 - 36% 30 .

79

: botox

;

;

- . : - . :

- 50% , - .

botox , - 3.500 , - - , .

New England Research Institute -

45%, 50%.

, - . - , - .

-. , - . , , - , - , , . , , , , - , , . , 25-55 . , 20%, . 31%, , , -, .

- , , - , . -, PLOS ONE, - -, - . -, 0,8 -

. O - . 80 -, 8 , : 0,8 . x 72 = 57,6 - . , - 10 . , - 15 . .

80 / - 2016

! Ph.B (Pharma & Health Business)!

( )

&

: 50 : 30

: 0 : 90

( )

: 10

( ..)

: (089/470271-92 / IBAN GR46 0110 0890 0000 0894 7027 192)

ETHOS MEDIA .. . fax 210 998 4953, . .

-

*

*

..

.

E-MAIL .

FAX * *

*

: , 210 998 4909, [email protected] : ETHOS MEDA S.A., 29, 174 56 , Fax: 210 998 4953

!

80 / - 2016

! Ph.B (Pharma & Health Business)!

( )

&

: 50 : 30

: 70 : 90

( )

: 10

( ..)

: (089/470271-92 / IBAN GR46 0110 0890 0000 0894 7027 192)

ETHOS MEDIA .. . fax 210 998 4953, . .

-

*

*

..

.

E-MAIL .

FAX * *

*

: , 210 998 4909, [email protected] : ETHOS MEDIA S.A., 29, 174 56 , Fax: 210 998 4953

Ph.B , , e-mail!

, . e-book , rich media (video, , flash animations),

hyperlinks, , ...!

!

80.indd 80 26/2/2016 3:12:11

PFI

-02-

FEB

16

Pfizer, - , 1849 .

, .

C

M

Y

CM

MY

CY

CMY

K

AbbVie_bestworkplaces2016TEL2_21x28.pdf 1 4/7/16 2:00 PM

GR1603458162


#035 -2 0 1 6


pi

pi


001 EX.indd 1 3/3/2016 7:50:57 pi

/ #0

35

/

-

2

01

6ISSN

: 224

1-09

61


/ #03

7 /

-

2016


#035 -2 0 1 6


pi

pi


001 EX.indd 1 3/3/2016 7:50:57 pi

/ #0

35

/

-

2

01

6ISSN

: 224

1-09

61


#037- 2 0 1 6

Jean-Michel Malbrancq

C

Pharma & Health Business #37, Μαΐος-Ιούνιος 2016

Documents

Transcript of Pharma & Health Business #37, Μαΐος-Ιούνιος 2016